1. Home
  2. ATCX vs AKTX Comparison

ATCX vs AKTX Comparison

Compare ATCX & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlas Critical Minerals Corporation Common Stock

ATCX

Atlas Critical Minerals Corporation Common Stock

HOLD

Current Price

$3.12

Market Cap

18.8M

Sector

N/A

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$9.70

Market Cap

15.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATCX
AKTX
Founded
2016
N/A
Country
Brazil
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8M
15.4M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
ATCX
AKTX
Price
$3.12
$9.70
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$13.75
★ $33.50
AVG Volume (30 Days)
6.5K
★ 80.1K
Earning Date
03-16-2023
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$827,667.00
N/A
Revenue Next Year
$166.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$0.12
52 Week High
$14.01
$29.32

Technical Indicators

Market Signals
Indicator
ATCX
AKTX
Relative Strength Index (RSI) 39.81 49.63
Support Level $2.88 $9.20
Resistance Level $3.26 $12.15
Average True Range (ATR) 0.18 1.13
MACD -0.02 -0.12
Stochastic Oscillator 38.89 33.15

Price Performance

Historical Comparison
ATCX
AKTX

About ATCX Atlas Critical Minerals Corporation Common Stock

Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: